At the beginning of the intervention, eligible patients with T2D and ASCVD, CKD, and/or HF were identified by the Patient Report as potentially benefiting from SGLT2 inhibitor or GLP-1 RA initiation. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.